Arbutus Biopharma (ABUS) Appoints Lindsay Androski as CEO, Announces Board Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025 7:00 AM ESTWARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Â Arbutus Biopharma Corporation (Nasdaq: ABUS) (Arbutus or the Company), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Companys Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Companys board of directors.
Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and... More
